Danaher CorporationDHR’s adjusted earnings for the second quarter of 2025 came in at $1.80 per share, surpassing the Zacks Consensus Estimate of $1.64. The net income rose 4.7% compared to the previous year.
Danaher announced net sales of $5.94 billion, surpassing the expected figure of $5.84 billion. This represents a 3.5% rise compared to the previous year, fueled by strong results across all segments.
Support kami, ada hadiah spesial untuk anda.
Klik di sini: https://indonesiacrowd.com/support-bonus/
DHR’s primary sales rose by 1.5% compared to the previous year during the quarter. Exchange rate fluctuations contributed positively by 2%.
DHR’s Segmental Discussion
Revenue from the Life Sciences segment reached $1.78 billion, representing a 0.5% increase compared to the previous year. The segment’s revenue was anticipated to be $1.71 billion. Nevertheless, core sales declined by 2.5% year over year. Acquisitions and divestitures contributed positively to segment sales by 1.5%, as did foreign currency translations, which also added 1.5%. The operating loss amounted to $239 million, compared to an operating profit of $233 million in the same quarter last year.
Revenues in the Diagnostics segment reached $2.31 billion, representing a 2% increase compared to the previous year. Our projected revenue was $2.29 billion. Core sales rose by 2% year-over-year, with foreign exchange contributing an additional 0.5% to sales. Nevertheless, acquisitions and divestitures had a negative effect of 0.5% on sales. Operating profit amounted to $554 million, a slight decrease of 0.4% from the prior year.
Support us — there's a special gift for you.
Click here: https://indonesiacrowd.com/support-bonus/
Biotechnology segment revenues reached $1.85 billion, representing an 8% increase compared to the previous year. We had projected $1.83 billion. Core sales rose by 6% over the same period, with foreign-exchange effects contributing an additional 2%. Operating profit amounted to $531 million, up 14.9% from the prior year.
Danaher’s Margin Profile
In the second quarter, Danaher’s cost of goods sold rose by 4.2% compared to the previous year, reaching $2.41 billion. Gross profit amounted to $3.52 billion, reflecting a 2.8% increase from the same period last year. The gross margin stood at 59.3%, slightly down from 59.7% in the corresponding quarter of the previous year.
Sales, general, and administrative costs amounted to $2.36 billion, reflecting a 26.3% rise compared to the previous year. Research and development expenses reached $403 million, representing an increase of 3.1% from the prior year.
Danaher’s operating profit fell by 34.9% compared to the previous year, reaching $760 million. The operating margin declined to 12.8%, down from 20.3% in the same quarter last year.
DHR’s Statement of Financial Position and Cash Flows
After the second quarter, DHR reported cash and equivalents of $2.96 billion, up from $2.1 billion at the end of 2024. The company’s long-term debt stood at $16.9 billion by the end of the quarter, compared to $15.5 billion at the end of December 2024.
Danaher produced net cash of $2.64 billion from operations during the first half of 2025, compared to $3.16 billion in the same period of the prior year. Capital spending reached $493 million in the same timeframe, representing a 14.7% decline from the previous year. Adjusted free cash flow fell by 16.5% year-over-year to $2.15 billion for the first six months of 2025.
During the same time frame, DHR distributed $423 million in dividends, representing a 12.2% increase compared to the previous year.
Danaher’s Outlook
For the third quarter, Danaher anticipates adjusted core sales from ongoing operations to rise by a low single-digit percentage compared to the previous year.
The metric is projected to rise by about 3% compared to the previous year in 2025. The company anticipates adjusted earnings to be between $7.70 and $7.80 per share, up from the earlier forecast of $7.60 to $7.75.
DHR’s Zacks Rank
The company currently has a Zacks Rank of 4 (Sell).
You can see the full list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Performance of Other Companies
Quest Diagnostics Inc.DGX’s adjusted earnings per share (EPS) for the second quarter of 2025 was $2.62, surpassing the Zacks Consensus Estimate by 1.9%. This result also outperformed the adjusted figure from the same period last year by 11.5%.
Second-quarter revenues increased by 15.2% compared to the previous year, reaching $2.76 billion. This figure exceeded the Zacks Consensus Estimate by 1.5%.
Tenet Healthcare CorporationTHC posted a profit of $4.02 per share during the second quarter of 2025, surpassing the Zacks Consensus Estimate of $2.84. This is an increase from earnings of $2.31 per share in the same period last year.
The firm reported revenues of $5.27 billion for the quarter, exceeding the Zacks Consensus Estimate by 2.43%. This is an increase from the $5.1 billion in revenues recorded during the same period last year.
Medpace Holdings, Inc.MEDP reported quarterly earnings of $3.1 per share for the second quarter of 2025, exceeding the Zacks Consensus Estimate of $3 per share. This is an increase from earnings of $2.75 per share from the previous year.
Medpace reported revenue of $603.31 million for the quarter ending June 2025, exceeding the Zacks Consensus Estimate by 11.48%. This is an increase from the $528.1 million in revenues recorded during the same period in the previous year.
This piece was first published on Zacks Investment Research ().
